ObesityWeek 2026: New GLP-1 Drug Delivers Nearly 20% Weight Loss in Phase 3 Trial
Ribupatide emerges as another potential Zepbound competitor, with impressive weight loss and surprisingly low treatment discontinuation rates.
Ribupatide emerges as another potential Zepbound competitor, with impressive weight loss and surprisingly low treatment discontinuation rates.
Find obesity and metabolic clinical trials that may be relevant to you, then connect directly with the study team when contact information is available.
Find My Trial19,282 recruiting studies tracked across 1150 treatments — sourced from ClinicalTrials.gov.
The experimental quadruple agonist showed greater weight loss and less relative lean-mass loss in animal studies. Human trials could begin in 2027.
On The Pen's flagship podcast — obesity medicine, unfiltered.
Obesity.News
Breaking GLP-1 news, drug development, access updates, and patient-centered analysis, all in one place.
Empowering you to have better conversations with your doctor.
On The Pen covers obesity medicine from the patient's side of the exam table — GLP-1s, access, and the science, reported plainly.
Sponsors & Partners